Latest news with #GAD
Hindustan Times
2 days ago
- Politics
- Hindustan Times
Fire breaks out in lobby area of J&K assembly
A fire broke out inside the lobby area of the Jammu and Kashmir legislative assembly complex here on Wednesday causing significant damage to the property that reportedly included photographs of former governors, lieutenant governors, speakers, chief ministers and best legislators. Incharge secretary of the legislative assembly, Manoj Kumar Pandit said, 'A fire broke out around 9 am in the lobby, probably due to a short circuit. According to preliminary information, some two to three sofas and photographs were damaged in it.' 'No FIR has been lodged as yet. However, we have our own police within the secretariat,' he added. However, a senior police official at the civil secretariat said that they do not have executive powers to take cognisance of such incidents. 'Cognisance of such incidents has to be taken by the local police following complaint lodged by the victim. We are here for the purpose of security,' he said. The secretary of J&K's law, justice and parliamentary affairs department, Achal Sethi, said, 'We received preliminary reports of a fire incident in the lobby of J&K legislative assembly secretariat, probably due to a short circuit. I had sent some officers there to assess the situation. We have also sought a report from the assembly secretariat.' However, the law secretary feigned ignorance about any FIR having been lodged with the police. The fire also gutted several chairs, and other infrastructure, reportedly worth lakh of rupees. Officials divulged that two fire tenders were rushed to the spot to extinguish the fire. No casualties were reported in the incident. It may be stated here that just before the Budget session held here in March this year, the assembly complex had undergone a repair and renovation work at a cost of over ₹2 crore. 'During the repair and renovation works, photographs of former governors, LGs, speakers, CMs, Dy CMs and MLAs were removed from the walls of the lobby,' said an official, who declined to be named. The move had invited the ire of chief minister Omar Abdullah during his visit to the assembly complex before Budget session, he added. 'After Omar expressed his displeasure, the photographs were reinstalled but majority of them were burnt in the fire incident today,' he said. The official stated that in the past one year and a half, four fire incidents took place but no inquiry report has seen the light of the day. 'An old building of the MLAs hostel in Srinagar was burnt in a fire incident followed by two similar fire incidents at MLA hostel at Jammu and new building of the MLAs in Srinagar. Today's incident was fourth in the past one year and a half. In all the three previous incidents, inquiries were mere eye-wash and violative of laid procedures and delegation of powers', he said. The official informed that inquiries in such incidents have to be ordered by general administration department (GAD), which appoints IAS or JKAS officers to conduct the probe. The probe has to be independent and it should not be conducted by the department itself where any incident or lapse has taken place, he said. The official confided that the past three inquiries ordered by incharge secretary J&K legislative assembly secretariat have not seen the light of the day. 'Further, they were conducted by a deputy secretary of the legislative assembly secretariat which had two non-gazetted officers as members, one of them an employee of the watch and ward staff,' he said. While in-charge secretary legislative assembly secretariat assured to look into violation of rules, a top official of the law department admitted that corrective measures were urgently needed. Repeated calls and messages to the commissioner secretary GAD, M Raju went unanswered.
Time of India
2 days ago
- Health
- Time of India
Kamaraddy man, addicted to toddy, hospitalised in Saudi Arabia
Hyderabad: A Kamaraddy-based worker has been hospitalised in Saudi Arabia after falling ill, allegedly due to adulterated toddy which he often consumed in his hometown. He was reportedly suffering from a mental health issue and was admitted to King Salman bin Abdulaziz Medical City Hospital in Medina. Tired of too many ads? go ad free now Ramu was reportedly accustomed to drinking adulterated toddy before he left for Saudi Arabia last month. Some toddy compounds violate the rules by mixing Chloral Hydrate, Diazepam and Alprazolam into the toddy, which intoxicates the person who consumes it. However, this has a debilitating effect on the individual, affecting their nervous system. On Tuesday, Ramu's family approached Pravasi Praja Vani at Praja Bhavan in Hyderabad and submitted a memorandum addressed to chief minister A Revanth Reddy, urging him to arrange for the worker to receive medical treatment in India. On the same day, the General Administration Department (GAD) of the Telangana govt sent a letter to the Consul General of India in Jeddah, requesting assistance in transferring the patient to India. "The police and revenue authorities must also raise awareness of the harmful effects of consuming such adulterated toddy," said Mandha Bheem Reddy, TPCC NRI cell convenor, adding that this was necessary in several districts.
Time of India
3 days ago
- Business
- Time of India
New rules for retired officials' appointments in Maharashtra
Mumbai: In a bid to regulate the ad-hoc appointment of retired babus and officials into various govt departments and semi-govt organisations, the state govt on Tuesday issued guidelines on their contractual appointment. The new guidelines state that retired officials must only be appointed through a panel system on a contractual basis for 'specific work' for a period of one year at a time and for a maximum of three years only. The govt also said that no administrative or financial authority can be conferred on persons appointed on a contractual basis. "A transparent system should be adopted while making appointments for 'specific work' through a panel contract method. Applications should be invited from eligible retired officers for 'specific work' by giving advertisements. The validity of the panel shall be for a maximum of three years, and the panel shall be reviewed annually. The competent authority should determine the period for completion of the work, taking into account the nature and scope of the particular work," a Govt Resolution (GR) issued by the General Administration Department (GAD) stated. Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Giao dịch vàng CFDs với mức chênh lệch giá thấp nhất IC Markets Đăng ký Undo "The number of persons to be appointed on a contract basis should be a maximum of 10% of the total sanctioned number of posts in the office/establishment. While preparing the proposal for appointment on a contract basis, the nature of the work, contingency, and public interest should be taken into consideration. Appointment on a contract basis for the said work should be given for a maximum period of one year at a time. Persons appointed on a contractual basis can continue to work only up to the age of 65 years. However, the services of a person whose services are required to be continued beyond that period may be continued by the competent authority with the approval of the officer/authority immediately above him. However, in any case, persons appointed on a contractual basis can continue to work only up to the age of 70 years," the GR stated. "Since the appointment is made on a contractual basis, the person concerned will not have the right/entitlement to inclusion/admission in any cadre of the govt or to receive any other benefits of regular service. The person appointed on a contract basis should not be engaged in any professional activity which would interfere with the performance of the assigned services. It will be necessary to disclose any conflict of interest that may arise for the person appointed on a contractual basis. Persons appointed on a contractual basis will be required to maintain confidentiality regarding the documents/information base received by them. The consent of the GAD and the Finance Department will not be required while making appointments on a contractual basis," the GR stated.
Time Business News
05-06-2025
- Health
- Time Business News
Anxiety Disorders and Substance Abuse: A Closer Look
Introduction Anxiety disorders are among the most common mental health conditions globally, yet their intersection with substance abuse often remains underappreciated. This co-occurrence creates a tangled web of symptoms, behaviors, and consequences that complicate both diagnosis and treatment. Understanding the intricate relationship between anxiety and substance use is crucial for crafting effective intervention and recovery strategies. Understanding the Duration of Fluconazole in the Body Fluconazole, an antifungal medication commonly used to treat yeast infections, has a relatively long half-life, which allows it to remain in the body for an extended period. Typically, a single dose can stay in your system for up to 72 hours, but traces may persist for several days depending on individual factors such as metabolism,how long does fluconazole stay in your system age, liver function, and dosage. In people with normal liver function, the drug is gradually eliminated, but in those with impaired liver or kidney function, it may take longer. If you're concerned about how long fluconazole stays in your system, consult your healthcare provider. Understanding Anxiety Disorders Types of Anxiety Disorders Anxiety disorders encompass a wide spectrum of conditions. Generalized Anxiety Disorder (GAD), Panic Disorder, Social Anxiety Disorder, Specific Phobias, and Obsessive-Compulsive Disorder (OCD) each manifest with distinct behavioral patterns. While varied in presentation, all share the hallmark of persistent, excessive worry that interferes with daily functioning. Symptoms and Causes Symptoms range from constant restlessness and irritability to heart palpitations and intrusive thoughts. Causes are multifaceted—genetic predisposition, childhood trauma, chronic stress, and imbalances in brain chemistry all play a role. Cortisol dysregulation and amygdala hyperactivity, in particular, fuel the cycle of fear and avoidance behaviors. The Link Between Anxiety and Substance Abuse Self-Medication Hypothesis Many individuals with untreated anxiety turn to substances in an attempt to self-soothe. This self-medication hypothesis posits that drugs or alcohol temporarily blunt the emotional distress caused by anxiety, offering fleeting relief. However, this escape mechanism often spirals into dependency. Neurobiological Overlap Shared neural circuitry—particularly in the limbic system—suggests a biological basis for this dual affliction. Dopaminergic dysregulation and impaired executive function contribute to poor impulse control, making substance misuse more likely in those already battling anxiety. The comorbidity is not coincidental; it is rooted in brain-based vulnerabilities. Common Substances Abused by Individuals with Anxiety Alcohol as a Coping Mechanism Alcohol is frequently used to 'take the edge off.' Its initial anxiolytic effects mask a darker truth: chronic use exacerbates anxiety symptoms. The rebound effect—where anxiety surges once the alcohol wears off—deepens dependence and emotional instability. Prescription Drug Misuse Benzodiazepines, often prescribed for anxiety, can become a double-edged sword. While effective short-term, their high potential for dependence poses a significant risk. Tolerance builds rapidly, leading many to increase dosages unsupervised or seek illicit sources. Illicit Drugs and Escape Behavior Stimulants like cocaine and methamphetamine may appear paradoxical choices, but some use them to combat fatigue and gain social confidence. Hallucinogens and opioids, on the other hand, offer a dissociative escape. These patterns reveal the lengths to which individuals will go to quiet the internal chaos. Dual Diagnosis: Challenges in Co-Occurring Disorders Diagnostic Complexities The symptoms of anxiety and substance use disorders often mimic or mask each other, creating a diagnostic labyrinth. Is the anxiety substance-induced, or did it precede the drug use? Clinicians must carefully dissect patient histories to avoid misdiagnosis. Treatment Implications Dual diagnosis demands an integrative approach. Treating substance abuse in isolation ignores the root causes of self-medication, while treating anxiety without addressing addiction ensures relapse. A nuanced, synchronized treatment plan is essential. Evidence-Based Treatment Approaches Integrated Treatment Models Effective recovery hinges on integrated care—where mental health and addiction services work in tandem. Coordinated treatment fosters better communication between providers and aligns goals, reducing the risk of fragmented care. Cognitive Behavioral Therapy (CBT) CBT remains a cornerstone of treatment. By identifying and restructuring maladaptive thought patterns, patients gain tools to manage anxiety without relying on substances. The therapy is skill-based, empowering, and deeply transformative. Medication-Assisted Treatment (MAT) In cases of severe addiction, MAT—using medications like buprenorphine, methadone, or naltrexone—can stabilize withdrawal and support long-term abstinence. When combined with psychotherapy, MAT can address both physiological and psychological dimensions of recovery. The Role of Prevention and Early Intervention Identifying At-Risk Individuals Early identification of anxiety symptoms—particularly in adolescents and young adults—can curtail the trajectory toward substance misuse. School-based screenings, routine mental health checkups, and trauma-informed care are vital. Community and Family-Based Strategies Strong social support systems can act as a buffer. Family therapy, community outreach, and psychoeducation reduce stigma and encourage help-seeking behavior. When communities foster mental wellness, individuals are less likely to turn to substances for relief. Gabapentin is a prescription medication commonly used to treat nerve pain, seizures, and other neurological conditions. Although not classified as a controlled substance in many areas, it has gained attention for its potential misuse. Some individuals report experiencing feelings of euphoria or sedation, which raises concerns about whether you can get high on gabapentin. These effects are typically more pronounced at high doses or when combined with other substances, posing serious health risks. Misusing gabapentin Can You Get High on Gabapentin lead to physical dependence, withdrawal symptoms, and dangerous side effects, making it important to use the medication only as directed by a healthcare provider. Conclusion The intersection of anxiety disorders and substance abuse is a complex, often cyclical relationship that requires compassionate, comprehensive care. By acknowledging the neurobiological, psychological, and social underpinnings of this dual diagnosis, professionals can pave the way for more effective prevention and recovery. Addressing both conditions concurrently is not just beneficial—it is imperative. TIME BUSINESS NEWS
Business Wire
03-06-2025
- Business
- Business Wire
Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder
TORONTO--(BUSINESS WIRE)-- Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (' Cybin ' or the ' Company '), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that the United States Patent and Trademark Office has granted U.S. patent 12,318,477 in support of its CYB004 deuterated DMT program in development for the treatment of generalized anxiety disorder ('GAD'). The patent, which is expected to provide exclusivity until 2040, includes claims to novel formulations of DMT and deuterated isotopologues for intramuscular ('IM') injection, including CYB004. 'Patents are extremely valuable assets, and protection for our lead product candidates is a top priority for us,' said Doug Drysdale, Chief Executive Officer of Cybin. 'We believe that our CYB004 program has the potential to deliver short-duration, rapid-acting treatment for anxiety disorders and offer more patient-friendly dosing methods such as IM administration. The issuance of this additional patent in support of CYB004 adds further validation of this important program. Dosing is currently underway in our Phase 2 study evaluating CYB004 in generalized anxiety disorder, and we expect the study to complete around mid-year. I'm proud that Cybin has amassed one of the strongest IP portfolios in the sector with more than 90 granted patents and over 230 pending applications.' About Cybin Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. With industry leading proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin program, in Phase 3 development for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine program in a Phase 2 study for generalized anxiety disorder. The company also has a research pipeline of investigational, 5-HT-receptor focused compounds. Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit or follow the team on X, LinkedIn, YouTube and Instagram. Cautionary Notes and Forward-Looking Statements Certain statements in this news release relating to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as 'may', 'should', 'could', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe' or 'continue', or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company's expectations respecting the patent exclusivity period; plans to complete the Phase 2 GAD study around mid-year 2025; and the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders. These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: implications of the spread of a pandemic on the Company's operations; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; and the risk factors set out in each of the Company's management's discussion and analysis for the three and nine month periods ended December 31, 2024 and the Company's annual information form for the year ended March 31, 2024, which are available under the Company's profile on SEDAR+ and with the U.S. Securities and Exchange Commission on EDGAR at Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations. Neither the Cboe Canada nor the NYSE American LLC stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.
